ArticleJournal of experimental & clinical cancer research : CR2026
Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundPlatinum-resistant high-grade serous ovarian carcinoma (HGSOC) is a major clinical challenge, with high mortality rates and no effective therapeutic options. Metabolic adaptations-including enhanced lipid catabolism, oxidative phosphorylation (OXPHOS), and autophagy-are major drivers of chemoresistance; however, the molecular mechanisms underpinning this metabolic reprogramming remain poorly understood. Carboxylesterase 1 (CES1), an NF-κB-regulated neutral lipase, supports malignant cell survival under nutrient-depleted conditions in other cancers, but its role in HGSOC has not been explored.
methodsWe investigated the role of CES1 in i) epithelial ovarian cancer (EOC) cell lines across different histological subtypes, ii) primary HGSOC cells, iii) syngeneic and platinum-resistant HGSOC mouse models. Glucose and serum limitation was used to model metabolic stress associated with platinum resistance. CES1 activity was blocked both genetically and pharmacologically using the specific CES1 inhibitor GR-148672X. Metabolic profiling, survival analysis, lipid-droplet dynamics and autophagy assays were performed. Clinical significance was evaluated by analyzing The Cancer Genome Atlas (TCGA) cohort, stratified by chemotherapy response.
resultsMetabolic stress induced a shift from glycolysis to OXPHOS and promoted platinum resistance in EOC cells. This adaptation was coincident with an upregulation of CES1, which supported lipolysis, fatty acid oxidation, and autophagy/lipophagy. CES1 inhibition disrupted these processes leading to apoptosis/ferroptosis in platinum-resistant EOC lines. Oleate supplementation effectively reversed CES1-mediated biological effects, confirming their dependence on CES1-driven lipid mobilization. CES1 blockade also killed primary HGSOC cells with oxidative dependency for survival, impaired tumor growth and metastatic dissemination in Trp53
conclusionsCES1 is a key checkpoint governing metabolic plasticity in EOC including HGSOC, by linking lipid catabolism, OXPHOS, and autophagy to chemoresistance under conditions of metabolic pressure. Targeting CES1 selectively compromises tumor cell survival under nutrient deprivation, uncovering a metabolic vulnerability that may be exploited to treat aggressive platinum-resistant HGSOC that rely on OXPHOS to thrive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.